Dr. Reddy’s Laboratories (RDY) Receiving Somewhat Critical Media Coverage, Study Finds

Media stories about Dr. Reddy’s Laboratories (NYSE:RDY) have trended somewhat negative on Sunday, Accern Sentiment Analysis reports. The research group identifies negative and positive media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Dr. Reddy’s Laboratories earned a media sentiment score of -0.02 on Accern’s scale. Accern also gave press coverage about the company an impact score of 44.9277118117777 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

RDY stock traded down $0.90 on Friday, reaching $33.16. The company had a trading volume of 376,483 shares, compared to its average volume of 252,948. The company has a market capitalization of $5,498.89, a PE ratio of 35.66 and a beta of 0.24. The company has a current ratio of 1.50, a quick ratio of 1.13 and a debt-to-equity ratio of 0.20. Dr. Reddy’s Laboratories has a 1-year low of $29.83 and a 1-year high of $42.97.

How to Become a New Pot Stock Millionaire

Dr. Reddy’s Laboratories (NYSE:RDY) last released its earnings results on Thursday, January 25th. The company reported $0.41 EPS for the quarter. The business had revenue of $596.00 million for the quarter. Dr. Reddy’s Laboratories had a return on equity of 8.79% and a net margin of 6.95%. equities research analysts predict that Dr. Reddy’s Laboratories will post 1.07 EPS for the current year.

Several research firms have recently weighed in on RDY. ValuEngine cut shares of Dr. Reddy’s Laboratories from a “hold” rating to a “sell” rating in a report on Friday, February 2nd. Zacks Investment Research raised Dr. Reddy’s Laboratories from a “sell” rating to a “hold” rating in a research note on Tuesday, January 2nd. Three equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $30.51.

TRADEMARK VIOLATION NOTICE: This piece was first posted by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this piece on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The legal version of this piece can be viewed at https://sportsperspectives.com/2018/03/19/dr-reddys-laboratories-rdy-receiving-somewhat-critical-media-coverage-study-finds-2.html.

About Dr. Reddy’s Laboratories

Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosage with therapeutic equivalence to branded formulations.

Insider Buying and Selling by Quarter for Dr. Reddy`s Laboratories (NYSE:RDY)

Receive News & Ratings for Dr. Reddy's Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dr. Reddy's Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply